glucocorticoid-induced osteoporosis
Conditions
Interventions
Bisphosphonate group: receive alendronate 35 mg/week or risedronate 17.5 mg/week for 24 months
Teriparatide group
0.002mg/day subcutaneouly for 24 months
Sponsors
Department of Rheumatology & Clinical Immunology,Saitama Medical Center, Saitama Medical Universitity
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who are initially treated with more than 10 mg/day of glucocorticoid (prednisolone) for more than 3 months or scheduled to be treated for more than 3 months.
Exclusion criteria
Exclusion criteria: 1) Patients who have serious renal disorder (egfr < 35 ml /min or cr > 1.5 mg/ml). 2)Patient who has a history of renal stone past 5 years. 3)Patients with primary or secondary hyperparathyroidism. 4)Patients with hyperthyroidism or hypothyroidism. 5)Patients who are considered to be contraindicated for bisphosphonates or teriparatide. 6)Patients who are treated with warfarin. 7)Patients who have experiences of receiving drugs having influence on bone remodeling within 6 months at inclusion of the study (pth,bisphosphonates, estrogen , vitamin d3, vitamin k2, serm (raloxifene, bazedoxifene), calcitonin, Ipriflavone, steroids) 8) Patients who are thought to be inappropriate for this study by physician.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptomatic vertebral fractures, those are determined by conventional thoracic and spinal radiographs in lateral and antero-posterior projections at any time during study. | — |
Secondary
| Measure | Time frame |
|---|---|
| Non symptomatic vertebral fractures and non-vertebral fractures deetermined by plain X-ray. Bone mineral density values, those are measured at the lumbar spine. The serum levels of NTX, osteocalcin, 25(OH)vitamin D, growth hormone (GH) and IGF-1. | — |
Countries
Japan
Contacts
Public ContactHirofumi Takei
Saitama Medical Center, Saitama Medical Universitity Department of Rheumatology & Clinical Immunology
Outcome results
None listed